NASDAQ:VECT VectivBio (VECT) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free VECT Stock Alerts $16.85 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$16.85▼$16.8550-Day Range$16.85▼$16.8552-Week Range$4.25▼$16.98VolumeN/AAverage Volume545,546 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends Get VectivBio alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About VectivBio Stock (NASDAQ:VECT)VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.Read More VECT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VECT Stock News HeadlinesMay 29, 2024 | msn.comCompare with VectivBio Holding AG (VECT)May 15, 2024 | finance.yahoo.comenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsMay 14, 2024 | finanznachrichten.deVicore Pharma Holding: Vicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finance.yahoo.comVicore Expands and Strengthens its Board of DirectorsApril 5, 2024 | uk.finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthMarch 18, 2024 | msn.comPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 1, 2024 | msn.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyFebruary 29, 2024 | reuters.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | benzinga.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | ft.comOnly two sleeps left until February 31!February 22, 2024 | finance.yahoo.comShort Bowel Syndrome Market Size and Share is Anticipated to Surge During the Study Period (2020–2034) | DelveInsightFebruary 16, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call TranscriptDecember 13, 2023 | msn.comIronwood seals the deal on VectivBio mergerDecember 12, 2023 | finance.yahoo.comIronwood Announces the Completion of Squeeze-Out Merger With VectivBioNovember 15, 2023 | tmcnet.comReverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous CytokinesNovember 10, 2023 | msn.comIronwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesNovember 10, 2023 | markets.businessinsider.comAkash Tewari’s Buy Rating on Ironwood Pharma: Linzess Floor Trading and Apraglutide’s Promising FutureNovember 10, 2023 | markets.businessinsider.comHold Rating for Ironwood Pharma Driven by Stable Linzess Revenue and Anticipated Apraglutide Data, Despite T Cell Data DelayNovember 9, 2023 | finance.yahoo.comIronwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year GuidanceOctober 27, 2023 | msn.comIronwood Pharmaceuticals: The Right Play NowOctober 16, 2023 | markets.businessinsider.comIronwood Pharmaceuticals’ Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler’s Buy RatingSeptember 7, 2023 | finance.yahoo.comWhy Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?August 23, 2023 | markets.businessinsider.comEQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 23, 2023 | finance.yahoo.comAbivax Appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 9, 2023 | msn.comIronwood's (IRWD) Reports Q2 Loss, Linzess Volume RisesSee More Headlines Receive VECT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VECT CUSIPN/A CIK1836379 Webvectivbio.com Phone41-61-551-3030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$27.34 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book2.69Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Luca Santarelli M.D. (Age 53)Founder, CEO & Director Ms. Claudia D'Augusta Ph.D. (Age 53)Chief Financial Officer Dr. Christian Meyer M.D. (Age 56)Ph.D., Chief Operating Officer Dr. Alain Bernard Ph.D. (Age 66)Chief Technology Officer Mr. Patrick MalloySr. VP of Investor Relations & Strategic CommunicationsMr. Scott Applebaum (Age 56)Chief Legal Officer & Corp. Sec. Mr. Michael SteiningerSr. VP & Head of HRMr. Kevin Harris M.B.A. (Age 52)Chief Commercial Officer Dr. Sarah Holland Ph.D. (Age 60)Chief Bus. Officer Dr. Omar Khwaja M.D. (Age 53)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsKymera TherapeuticsNASDAQ:KYMRVericelNASDAQ:VCELImmunocoreNASDAQ:IMCRBeam TherapeuticsNASDAQ:BEAMRecursion PharmaceuticalsNASDAQ:RXRXView All Competitors VECT Stock Analysis - Frequently Asked Questions How have VECT shares performed in 2024? VectivBio's stock was trading at $16.85 on January 1st, 2024. Since then, VECT shares have increased by 0.0% and is now trading at $16.85. View the best growth stocks for 2024 here. When did VectivBio IPO? VectivBio (VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at a price of $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of VectivBio? Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VECT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.